… This meta-analysis provides the most comprehensive summary to date of the evidence
on nintedanib, pirfenidone, and pirfenidone versus nintedanib treatment for IPF patients. We …

… Similarly, in an Expanded Access Program with pirfenidone in US patients, almost half of
patients who had dose modifications were able to return to the full dose [Citation74]. …

… , whereas pirfenidone is … assessed the safety profiles of two drugs. This study provides
evidence for the clinical safety and medication reference of pirfenidone and nintedanib for patients…

… and lung function tests for a comprehensive analysis of symptom relief. Results show that
early intervention with pirfenidone significantly reduces disease progression and preserves …

… , providers should also focus on comprehensive care of the patient to improve health-…
Patients treated with pirfenidone showed improvements in both objective cough counts and patient…

… to assess the incidence of drug-induced liver injury (DILI) associated with the use of pirfenidone
and nintedanib in patients … Their results did not encompass comprehensive information …

… In the PIPF-004 study, patients were assigned in a 2:1:2 ratio to receive pirfenidone at a …
(174 patients), pirfenidone at a dose of 1,197 mg per day (87 patients) or placebo (174 patients), …

… Our results indicated that nintedanib and pirfenidone have similar health-related quality of
life benefits. Nintedanib had a lower overall cost than pirfenidone, driven by a lower treatment …

… The present review aims to assess the effectiveness and … Pirfenidone has received less
comprehensive evaluation in SSc-ILD; however, there are still studies that have assessed its …

… Comprehensive analyses of safety outcomes in large, well-defined populations (∼1,299 …
Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary …